Oversubscribed round led by Picus Capital and Alven will fast-track clinical validation of AI-based Cancer- Biomarker Platform Polaris™, expand global reach, and unlock multi-billion-euro cancer diagnostics market.
Berlin, Germany – September 2025 – StratifAI, the AI biomarker company for precision oncology, has secured €12.5 million in an oversubscribed funding round. The funding will accelerate the clinical validation of its multimodal AI biomarker discovery platform, Polaris™.
The round was led by Picus Capital, with co-lead Alven, alongside Heliad, Talberg Capital (Rubin Ritter), Box Two Capital (Lars Langusch), and Begemann Capital (Jens Begemann). Existing backers Debiopharm, Arve Capital, Christian Haarburger also joined, deepening their commitment to StratifAI’s vision.
Despite advances in cancer care, biomarker discovery remains slow, costly, and limited in scope, leaving vast opportunities untapped. StratifAI’s fully digital, AI-driven approach is designed to accelerate biomarker discovery, reduce costs, addressing one of the largest unmet needs in oncology.
Redefining Biomarker Discovery
What once demanded costly, specialized techniques, Polaris™ now achieves from routine histology – delivering spatial insights into tumors at a scale not seen before. By integrating H&E histology with RNASeq gene expression data, the platform instantly links spatial tumor signals to patient outcomes: eliminating additional testing, reducing costs, and revealing new prognostic and predictive insights. The company sources tumor samples, generates highquality data, and expands a growing portfolio of spatial biomarkers while building a comprehensive multimodal reference dataset.
First Clinical Application: Polaris™ Breast
StratifAI’s first product, Polaris™ Breast, is designed to assess the risk of breast cancer recurrence. The newly secured capital will accelerate its clinical validation and advance regulatory approvals in both Europe and the United States. StratifAI is building collaborations with leading oncology institutions and pharmaceutical companies to generate the large-scale clinical evidence required for guideline inclusion and to drive real-world adoption. “The power of AI to gain valuable insights from human data – such as high-resolution cell scans – through pattern recognition far beyond human capabilities has the potential to unlock unseen exponential progress in healthcare. The breast cancer application already has a massive impact potential, but is only the tip of the iceberg, especially as we expand the types of input data“, said Robin Godenrath, Founding Partner & Managing Director at Picus.
“As digitization of histology expands, the data available will be immense. When paired with powerful AI, the potential for new discoveries and deeper disease understanding is unprecedented. StratifAI sits exactly at this intersection, with a powerful technology, leading medical centers, and a founding team whose ambition knows no limits”, added Maria Tahri, Alven.
Currently, StratifAI is expanding its world-class team and global footprint to ensure the platform reflects diverse patient populations. This strategic expansion uniquely positions StratifAI to lead the development of the next generation of cancer biomarkers. Its fully digital, AI-driven approach is set to unlock one of the largest untapped markets in cancer diagnostics by redefining how biomarkers are developed and delivered.
“This investment enables us to build a scalable regulatory framework for developing clinical grade AI diagnostics, expand our ecosystem with diverse, high quality clinical data, and deliver better tests to support treatment decision making,” said Omar El Nahhas, CEO and co-founder of StratifAI. “With the support of our investors, who bring deep expertise in rapid execution and global scaling, we are setting a new standard for faster, more accessible clinical decision-making tools. By prioritizing biological diversity in our data, we are developing solutions that are globally applicable and positioning StratifAI at the forefront of the market.”
About StratifAI
StratifAI is a precision oncology company advancing cancer diagnostics through the development of next-generation biomarkers. Its biomarker discovery platform, Polaris™, leverages multimodal AI to routinely available clinical data, identifying novel prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers. Scientific foundation of Polaris™ has been peer-reviewed in various Nature journals.
Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, helping refine adjuvant treatment options. Retrospectively validated on thousands of patients from Phase III trials and in real-world clinical settings, Polaris™ Breast is available for research-use only and is undergoing regulatory approval in the EU and US.
For more information, visit : www.stratifai.com